High-rolling investors have positioned themselves bullish on CRISPR Therapeutics (NASDAQ:CRSP), and it's important for retail traders to take note. \This activity came to our attention today ...

Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

Analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

A live webcast of the fireside chat will be available on the "Events & Present ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $41.92, moving -1.2% from the previous trading session.

Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...